Heterozygous HTRA1 Mutations Cause Cerebral Small Vessel Diseases: Genetic, Clinical, and Pathologic Findings From 3 Chinese Pedigrees

Tingyan Yao; Junge Zhu; Xiao Wu; Xuying Li; Yongjuan Fu; Yuan Wang; Zhanjun Wang; Fanci Xu; Hong Lai; Aini He; Lianghong Teng; Chaodong Wang; Haiqing Song

doi:10.1212/NXG.0000000000200044

Heterozygous HTRA1 Mutations Cause Cerebral Small Vessel Diseases: Genetic, Clinical, and Pathologic Findings From 3 Chinese Pedigrees

Neurol Genet. 2022 Dec 5;8(6):e200044. doi: 10.1212/NXG.0000000000200044. eCollection 2022 Dec.

Authors

Tingyan Yao¹, Junge Zhu¹, Xiao Wu¹, Xuying Li¹, Yongjuan Fu¹, Yuan Wang¹, Zhanjun Wang¹, Fanci Xu¹, Hong Lai¹, Aini He¹, Lianghong Teng¹, Chaodong Wang¹, Haiqing Song¹

Affiliation

¹ Department of Neurology (T.Y., J.Z., X.W., X.L., Y.W., Z.W., F.X., H.L., A.H., C.W., H.S.), Xuanwu Hospital of Capital Medical University; Institute of Genetics and Developmental Biology (X.L.), Chinese Academy of Sciences; and Department of Pathology (Y.F., L.T.), Xuanwu Hospital of Capital Medical University, Beijing, China.

Abstract

Background and objectives: Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is a rare hereditary cerebrovascular disease caused by homozygous or compound heterozygous variations in the high-temperature requirement A serine peptidase 1 (HTRA1) gene. However, several studies in recent years have found that some heterozygous HTRA1 mutations also cause cerebral small vessel disease (CSVD). The current study aims to report the novel genotypes, phenotypes, and histopathologic results of 3 pedigrees of CSVD with heterozygous HTRA1 mutation.

Methods: Three pedigrees of familiar CSVD, including 11 symptomatic patients and 3 asymptomatic carriers, were enrolled. Whole-exome sequencing was conducted in the probands for identifying rare variants, which were then evaluated for pathogenicity according to the American College of Medical Genetics and Genomics guidelines. Sanger sequencing was performed for validation of mutations in the probands and other family members. The protease activity was assayed for the novel mutations. All the participants received detailed clinical and imaging examinations and the corresponding results were concluded. Hematoma evacuation was performed for an intracerebral hemorrhage patient with the p.Q318H mutation, and the postoperative pathology including hematoma and cerebral small vessels were examined.

Results: Three novel heterozygous HTRA1 mutations (p.Q318H, p.V279M, and p.R274W) were detected in the 3 pedigrees. The protease activity was largely lost for all the mutations, confirming that they were loss-of-function mutations. The patients in each pedigree presented with typical clinical and imaging features of CVSD, and some of them displayed several new phenotypes including color blindness, hydrocephalus, and multiple arachnoid cysts. In addition, family 1 is the largest pedigree with heterozygous HTRA1 mutation so far and includes homozygous twins, displaying some variation in clinical phenotypes. More importantly, pathologic study of a patient with p.Q318H mutation showed hyalinization, luminal stenosis, loss of smooth muscle cells, splitting of the internal elastic lamina, and intramural hemorrhage/dissection-like structures.

Discussion: These findings broaden the mutational and clinical spectrum of heterozygous HTRA1-related CSVD. Pathologic features were similar with the previous heterozygous and homozygous cases. Moreover, clinical heterogeneity was revealed within the largest single family, and the mechanisms of the phenotypic heterogenetic remain unclear. Overall, heterozygous HTRA1-related CSVD should not be simply taken as a mild type of CARASIL as previously considered.